SG11202006905YA - Fc variants with enhanced binding to fcrn and prolonged half-life - Google Patents
Fc variants with enhanced binding to fcrn and prolonged half-lifeInfo
- Publication number
- SG11202006905YA SG11202006905YA SG11202006905YA SG11202006905YA SG11202006905YA SG 11202006905Y A SG11202006905Y A SG 11202006905YA SG 11202006905Y A SG11202006905Y A SG 11202006905YA SG 11202006905Y A SG11202006905Y A SG 11202006905YA SG 11202006905Y A SG11202006905Y A SG 11202006905YA
- Authority
- SG
- Singapore
- Prior art keywords
- fcrn
- variants
- life
- enhanced binding
- prolonged half
- Prior art date
Links
- 101150050927 Fcgrt gene Proteins 0.000 title 1
- 230000002035 prolonged effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622468P | 2018-01-26 | 2018-01-26 | |
| PCT/US2019/015204 WO2019147973A1 (en) | 2018-01-26 | 2019-01-25 | Fc variants with enhanced binding to fcrn and prolonged half-life |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006905YA true SG11202006905YA (en) | 2020-08-28 |
Family
ID=65520379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006905YA SG11202006905YA (en) | 2018-01-26 | 2019-01-25 | Fc variants with enhanced binding to fcrn and prolonged half-life |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20190263934A1 (enExample) |
| EP (1) | EP3743441A1 (enExample) |
| JP (2) | JP7399880B2 (enExample) |
| KR (2) | KR102748986B1 (enExample) |
| CN (2) | CN111788221A (enExample) |
| AU (2) | AU2019212638B2 (enExample) |
| BR (1) | BR112020015006A2 (enExample) |
| CA (1) | CA3089602A1 (enExample) |
| CO (1) | CO2020010269A2 (enExample) |
| IL (2) | IL276286B2 (enExample) |
| MX (2) | MX2020007882A (enExample) |
| MY (1) | MY203898A (enExample) |
| PH (1) | PH12020551134A1 (enExample) |
| SG (1) | SG11202006905YA (enExample) |
| TW (1) | TW201940512A (enExample) |
| WO (1) | WO2019147973A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019212638B2 (en) * | 2018-01-26 | 2025-04-03 | Genzyme Corporation | Fc variants with enhanced binding to FcRn and prolonged half-life |
| US20210024620A1 (en) * | 2019-07-25 | 2021-01-28 | Genzyme Corporation | Methods of Treating Antibody-Mediated Disorders with FcRn Antagonists |
| US11807687B2 (en) | 2019-10-03 | 2023-11-07 | Atyr Pharma, Inc. | Therapeutic compositions comprising anti-NRP2 antibodies |
| KR20230034954A (ko) * | 2020-05-11 | 2023-03-10 | 인베티엑스 인코포레이티드 | 개에서 치료제의 반감기를 증가시키기 위한 조성물 및 사용 방법 |
| JP2023547239A (ja) * | 2020-10-29 | 2023-11-09 | フォーマイコン アーゲー | Ａｃｅ２融合タンパク質及びその使用方法 |
| IL308733A (en) | 2021-05-27 | 2024-01-01 | Sanofi Sa | Fc variant with increased affinity for Fc receptors and improved thermal stability |
| US20250197514A1 (en) | 2021-08-20 | 2025-06-19 | Intervet Inc. | ANTIBODIES AND IgG FUSION PROTEINS WITH AN EXTENDED HALF-LIFE |
| US20240409619A1 (en) * | 2021-10-13 | 2024-12-12 | The Wistar Institute Of Anatomy And Biology | Antibodies for use against sars-cov-2 |
| TW202413419A (zh) | 2022-05-27 | 2024-04-01 | 法商賽諾菲公司 | 與ｎｋｐ４６和ｂｃｍａ變體結合之具有ｆｃ工程化的自然殺手（ｎｋ）細胞接合物 |
| CN116162171B (zh) * | 2022-10-13 | 2025-06-03 | 深圳市百士通科技开发有限公司 | 抗体突变方法在治疗性抗体药物中的应用 |
| EP4608859A1 (en) | 2022-10-25 | 2025-09-03 | Ablynx N.V. | Glycoengineered fc variant polypeptides with enhanced effector function |
| CN120303299A (zh) | 2022-12-05 | 2025-07-11 | 赛诺菲 | 转铁蛋白受体结合蛋白 |
| US20250154262A1 (en) | 2023-10-25 | 2025-05-15 | Ablynx N.V. | Fc DOMAIN VARIANTS WITH ENHANCED Fc RECEPTOR BINDING |
| WO2025101094A1 (en) * | 2023-11-08 | 2025-05-15 | Ооо «Geropharm» | Fc fragment polypeptide for producing therapeutically active fusion polypeptides and conjugates |
| WO2025149633A1 (en) | 2024-01-12 | 2025-07-17 | Laigo Bio B.V. | Bispecific antigen binding proteins |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994009817A1 (en) | 1992-11-04 | 1994-05-11 | City Of Hope | Novel antibody construct |
| EP0799244A1 (en) | 1995-10-16 | 1997-10-08 | Unilever N.V. | A bifunctional or bivalent antibody fragment analogue |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| KR101155191B1 (ko) * | 1999-01-15 | 2012-06-13 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| AU2001270609A1 (en) | 2000-06-30 | 2002-01-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| CN1871259A (zh) | 2003-08-22 | 2006-11-29 | 比奥根艾迪克Ma公司 | 具有改变的效应物功能的经改进的抗体和制备它的方法 |
| ZA200701715B (en) * | 2004-08-19 | 2008-07-30 | Genentech Inc | Polypeptide variants with altered effector function |
| EP2314618A3 (en) | 2004-11-12 | 2011-10-19 | Xencor Inc. | Fc variants with altered binding to FcRn |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8163881B2 (en) * | 2005-05-31 | 2012-04-24 | The Board Of Regents Of The University Of Texas System | Immunoglobulin molecules with improved characteristics |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| EP2373689A1 (en) * | 2008-12-12 | 2011-10-12 | MedImmune, LLC | Crystals and structure of a human igg fc variant with enhanced fcrn binding |
| JP5944831B2 (ja) * | 2009-12-23 | 2016-07-05 | シュニムネ ゲーエムベーハーＳＹＮＩＭＭＵＮＥ ＧｍｂＨ | 抗ｆｌｔ３抗体及びその使用方法 |
| WO2011089211A1 (en) * | 2010-01-22 | 2011-07-28 | Synimmune Gmbh | Anti-cd133 antibodies and methods of using the same |
| TWI743461B (zh) | 2011-03-28 | 2021-10-21 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| GB201112429D0 (en) * | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| US20150050269A1 (en) * | 2011-09-30 | 2015-02-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
| US20140294812A1 (en) * | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| KR102266819B1 (ko) * | 2013-04-29 | 2021-06-18 | 에프. 호프만-라 로슈 아게 | Fc-수용체 결합 개질된 비대칭 항체 및 이의 사용 방법 |
| BR112017006178A2 (pt) * | 2014-11-06 | 2018-05-02 | F. Hoffmann-La Roche Ag | região fc, anticorpos, formulação farmacêutica e usos dos anticorpos |
| AU2015345320A1 (en) | 2014-11-10 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-IL-1beta antibodies and methods of use |
| IL315729A (en) * | 2016-08-02 | 2024-11-01 | Visterra Inc | Fc region containing polypeptides and uses thereof |
| AU2019212638B2 (en) * | 2018-01-26 | 2025-04-03 | Genzyme Corporation | Fc variants with enhanced binding to FcRn and prolonged half-life |
-
2019
- 2019-01-25 AU AU2019212638A patent/AU2019212638B2/en active Active
- 2019-01-25 EP EP19707152.5A patent/EP3743441A1/en active Pending
- 2019-01-25 MY MYPI2020003848A patent/MY203898A/en unknown
- 2019-01-25 JP JP2020561607A patent/JP7399880B2/ja active Active
- 2019-01-25 KR KR1020207024432A patent/KR102748986B1/ko active Active
- 2019-01-25 US US16/258,080 patent/US20190263934A1/en active Pending
- 2019-01-25 BR BR112020015006-1A patent/BR112020015006A2/pt unknown
- 2019-01-25 KR KR1020247043107A patent/KR20250008975A/ko active Pending
- 2019-01-25 CN CN201980015900.4A patent/CN111788221A/zh active Pending
- 2019-01-25 SG SG11202006905YA patent/SG11202006905YA/en unknown
- 2019-01-25 TW TW108102958A patent/TW201940512A/zh unknown
- 2019-01-25 CA CA3089602A patent/CA3089602A1/en active Pending
- 2019-01-25 IL IL276286A patent/IL276286B2/en unknown
- 2019-01-25 MX MX2020007882A patent/MX2020007882A/es unknown
- 2019-01-25 WO PCT/US2019/015204 patent/WO2019147973A1/en not_active Ceased
- 2019-01-25 CN CN202411307275.XA patent/CN119350481A/zh active Pending
- 2019-01-25 IL IL318916A patent/IL318916A/en unknown
-
2020
- 2020-07-24 PH PH12020551134A patent/PH12020551134A1/en unknown
- 2020-07-24 MX MX2025009543A patent/MX2025009543A/es unknown
- 2020-08-20 CO CONC2020/0010269A patent/CO2020010269A2/es unknown
-
2023
- 2023-12-04 JP JP2023204313A patent/JP2024026255A/ja active Pending
-
2025
- 2025-06-26 AU AU2025204826A patent/AU2025204826A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250008975A (ko) | 2025-01-16 |
| PH12020551134A1 (en) | 2021-05-31 |
| JP7399880B2 (ja) | 2023-12-18 |
| AU2019212638A1 (en) | 2020-09-17 |
| IL318916A (en) | 2025-04-01 |
| JP2024026255A (ja) | 2024-02-28 |
| TW201940512A (zh) | 2019-10-16 |
| US20190263934A1 (en) | 2019-08-29 |
| EP3743441A1 (en) | 2020-12-02 |
| CA3089602A1 (en) | 2019-08-01 |
| IL276286A (en) | 2020-09-30 |
| JP2021511830A (ja) | 2021-05-13 |
| IL276286B1 (en) | 2025-03-01 |
| IL276286B2 (en) | 2025-07-01 |
| MX2020007882A (es) | 2020-12-03 |
| RU2020128177A (ru) | 2022-02-28 |
| WO2019147973A1 (en) | 2019-08-01 |
| AU2025204826A1 (en) | 2025-07-17 |
| MX2025009543A (es) | 2025-09-02 |
| KR20200115568A (ko) | 2020-10-07 |
| MY203898A (en) | 2024-07-23 |
| KR102748986B1 (ko) | 2025-01-02 |
| AU2019212638B2 (en) | 2025-04-03 |
| CN111788221A (zh) | 2020-10-16 |
| NZ767453A (en) | 2025-03-28 |
| CN119350481A (zh) | 2025-01-24 |
| BR112020015006A2 (pt) | 2020-12-29 |
| CO2020010269A2 (es) | 2020-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276286A (en) | FC variants with improved binding to FCRN and extended half-life | |
| IL276537A (en) | Antibodies bind to GPRC5D | |
| ZA201906813B (en) | Antibody binding specifically to muc1 and use thereof | |
| IL274371A (en) | Compounds that bind CD137 and PSMA | |
| EP3835318C0 (en) | FC REGION VARIANTS WITH MODIFIED FCRN AND PROTEIN LIGAND PROPERTIES MAINTAINED | |
| GB2549632B (en) | Fusion protein comprising three binding domains to 5T4 and CD3 | |
| DK3215528T3 (da) | Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder | |
| LT3592384T (lt) | Antikūnai, specifiškai besirišantys prie žmogaus il-1 r7 | |
| PT3355913T (pt) | Moléculas de ligação com cadeia j modificada | |
| IL261783B (en) | Transgenic immunoglobulins with a change in binding to fcrn | |
| SG11201505762XA (en) | Il-11r binding proteins and uses thereof | |
| PL3292145T3 (pl) | Mutanty fc ze zmodyfikowaną aktywnością funkcjonalną | |
| IL265350A (en) | An antibody that specifically binds to il-17a and its functional fragment | |
| PL3322726T3 (pl) | Przeciwciała wiążące się z sortyliną i hamujące wiązanie progranuliny | |
| IL266516A (en) | An antibody that binds specifically to cd66c and its use | |
| PT3020732T (pt) | Um conjugado de imunoglobulina fc que mantêm a afinidade de ligação do fragmento de imunoglobulina fc à fcrn | |
| GB2551806B (en) | Interface with buffered and direct pathways | |
| HK40035029A (en) | Fc variants with enhanced binding to fcrn and prolonged half-life | |
| GB2574206B (en) | Briquettes | |
| PT3502205T (pt) | Adesivo de madeira modificado com silano com estabilidade melhorada | |
| PL3081609T3 (pl) | Bitumiczne spoiwo klejące i jego zastosowanie | |
| EP3903032A4 (en) | MULTIFUNCTIONAL LIGHTER | |
| HK40100588A (zh) | 具有改变的fcrn结合的工程化免疫球蛋白 | |
| HK40092407A (zh) | 具有改变的fcrn结合的工程化免疫球蛋白 | |
| PL3362480T3 (pl) | Przeciwciało specyficznie wiążące się z ERBB3 i jego zastosowanie |